G. Yeh

Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.

A. Levin, D. Kornbrust, S. Henry, 2002, International immunopharmacology.

PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer--A GERCOR Study.

F. Bonnetain, P. Hammel, A. Gramont, 2015 .

Cancer chemotherapy: Progress and expectations, 1984

G. Curt, C. Allegra, R. Fine, 1984, Cancer.

Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.

W. Su, Jang-Yang Chang, P. Lin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer chemotherapy. Progress and expectations, 1984.

G. Curt, C. Allegra, R. Fine, 1984, Cancer.

A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer.

M. Tempero, A. Ko, W. Su, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors.

T. Chao, J. Chang, L. Chen, 2010 .

Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients

A. Cheng, Jang-Yang Chang, H. Shiah, 2008 .

Randomized phase II study of PEP02, irinotecan, or docetaxel as a second-line therapy in gastric or gastroesophageal junction adenocarcinoma.

J. Tabernero, D. Cunningham, Y. Chao, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.